Lupin Earnings Outlook
- All
- News
- Videos
-
US-China Trade Relations, Macro Data To Guide Markets: Experts
Index heavyweights like HDFC, ITC, Vodafone Idea, Lupin, Hindalco, Bajaj Auto and IOC are also expected to announce their Q4 earning results
-
Lupin's Market Value Falls By Nearly Rs 5,500 Crore In One Day. Here Is Why
North America sales at Lupin slumped 13 per cent in the fourth quarter, dragging down net profit to Rs 380 crore from Rs 748 crore a year earlier.
-
Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch...
-
Sensex Heads For Second Straight Fall; Lupin Drags
Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.
-
Lupin Falls 8% on Muted Growth Outlook
Lupin shares have been trading at rich valuations because of its strong revenue growth track record. However, after the recent earnings outlook its valuations look costly, which led to profit booking in the stock, say analysts.
-
US-China Trade Relations, Macro Data To Guide Markets: Experts
Index heavyweights like HDFC, ITC, Vodafone Idea, Lupin, Hindalco, Bajaj Auto and IOC are also expected to announce their Q4 earning results
-
Lupin's Market Value Falls By Nearly Rs 5,500 Crore In One Day. Here Is Why
North America sales at Lupin slumped 13 per cent in the fourth quarter, dragging down net profit to Rs 380 crore from Rs 748 crore a year earlier.
-
Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch...
-
Sensex Heads For Second Straight Fall; Lupin Drags
Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.
-
Lupin Falls 8% on Muted Growth Outlook
Lupin shares have been trading at rich valuations because of its strong revenue growth track record. However, after the recent earnings outlook its valuations look costly, which led to profit booking in the stock, say analysts.
